Pharmacokinetics of Benznidazole
Author Information
Author(s): P. Workman, R.A.S. White, M.I. Walton, L.N. Owen, P.R. Twentyman
Primary Institution: MRC Clinical Oncology and Radiotherapeutics Unit, University of Cambridge
Hypothesis
Benznidazole may serve as a chemosensitizer in combination with CCNU.
Conclusion
Benznidazole has suitable pharmacokinetic properties for clinical use as a chemosensitizer.
Supporting Evidence
- Benznidazole showed rapid absorption and complete bioavailability in mice and dogs.
- Elimination half-lives were longer for benznidazole compared to misonidazole.
- Tissue penetration of benznidazole was generally good, with high tumor/plasma ratios.
- Only about 5% of the administered dose was excreted unchanged in urine, indicating extensive metabolism.
Takeaway
Benznidazole is a drug that helps make cancer treatments work better, and it behaves well in the body.
Methodology
The study involved pharmacokinetic analysis in mice, dogs, and sheep using high-performance liquid chromatography.
Limitations
The study primarily involved animal models, which may not fully represent human responses.
Participant Demographics
Adult inbred male BALB/c and C3H/He mice, adult dogs (beagles and collie crossbreds), and sheep.
Statistical Information
Confidence Interval
95%
Want to read the original?
Access the complete publication on the publisher's website